MedTrace Logo

Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression

NCT02491242 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 155

Last updated 2018-07-02

No results posted yet for this study

Summary

The objective of this study was to evaluate the efficacy and safety, and evolution of causes leading to change, of dual therapies based in Dolutegravir in patients requiring a change of virologically effective antiretroviral therapy.

Conditions

  • HIV Infection

Interventions

OTHER

Dolutegravir in a dual therapy regimen

None. Patients initiating Dolutegravir-based dual therapy because of nucleoside analogues toxicity or intolerance will be followed up during a year

Sponsors & Collaborators

  • Asociacion para el Estudio de las Enfermedades Infecciosas

    lead NETWORK

Principal Investigators

  • Jose L Casado, MD, PhD · Ramon y Cajal Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-03-31
Completion
2018-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02491242 on ClinicalTrials.gov